Increased Plasma Thrombomodulin as a Vascular Endothelial Cell Marker in Patients With Thrombotic Thrombocytopenic Purpura and Hemolytic Uremic Syndrome

Abstract

Several hemostatic and vascular endothelial cell markers were measured in 39 patients with thrombotic thrombocytopenic purpura (TTP)/hemolytic uremic syndrome (HUS) and in 20 healthy volunteers to examine the relationship between the occurrence of hemostatic abnormality or vascular endothelial cell injury and patient outcome. The plasma levels of von Willebrand factor, tissue plasminogen activator (TPA), plasminogen activator inhibitor (PAI-1), and the TPA-PAI-1 complex were significantly increased in TTP/HUS patients; however, the levels of these markers were not significantly different between TTP/HUS patients who survived and those who died, suggesting that these markers might not be directly related to outcome. The plasma levels of soluble granule membrane protein (GMP)-140 were significantly higher in TTP/ HUS patients than in healthy volunteers, suggesting that platelets and vascular endothelial cells are activated or injured in TTP/HUS. There was no significant difference in GMP-140 levels between TTP/HUS patients with good and poor prognoses ; this may be owing to the release of GMP-140 from platelets. The plasma thrombomodulin (TM) levels in TTP/ HUS patients were significantly higher than in healthy volunteers; the plasma TM levels were significantly higher in patients who died than in patients who survived. These findings showed that TM levels reflect the outcome and that the outcome of TTP/HUS depends on the presence vascular endothelial cell injury. The plasma protein C and antithrombin levels were markedly reduced in TTP/HUS patients who died compared with those who survived. These findings suggest that reduced plasma antithrombin and protein C may be useful markers of systemic vascular endothelial injury. In conclusion, the results of this study showed that the outcome of TTP/HUS is related to vascular endothelial cell injury and that plasma TM, antithrombin, and protein C levels may be useful markers of systemic vascular endothelial cell injury.

Keywords

Thrombomodulin Thrombotic thrombocytopenic purpura Hemolytic uremic syndrome

References

Bukouski RM Thrombotic thrombocytopenic purpura. A review. Prog Hemost Thromb 1982;6:287.

Amorosi EL Ultmann JE Thrombotic thrombocytopenic purpura: report of the 16 cases and review of the literature. Medicine (Bal— timore ) 1966;45:139.

Moschcowitz E. Hyaline thrombosis of the terminal arteriotes and capillaries: a hitherto undescribed disease. Proc N Y Pathol Soc 1924;24:21.

Gasser C. , Gautier E. Steck A , et al. Hamolytisch uramische syndrome: bilateral Nierenrindennekrosen bei akuten erworbenen Anamien. Schweiz Med Wochenschr 1955;85:905.

Wada H. , Kaneko T. , Ohiwa M. , et al. Plasma cytokine levels in thrombotic thrombocytopenic purpura . Am J Hematol 1992;40: 167.

Wada H. , Kaneko T. , Ohiwa M. , et al. Increased levels of vascular endothelial cell markers in thrombotic thrombocytopenic purpura. Am J Hematol 1993 :44:101.

Byrness JJ Moake JL. Thrombotic thrombocytopenic purpra and the haemolytic uraemic syndrome: evolving concepts of pathogenesis and therapy. Clin Hematol 1986;15:413.

Remmuzi G. HUS and TTP: variable expression of a single entity. Kidney Int 1987:32:292.

Spika JS , Parsons JE , Nordenberg D. , et al. Hemolytic uremic syndrome and diarrhea associated with Escherichia coli 0157:H7 in a day care center. J Pediatr 1986;109:287.

10.

Rowe C. Epidemiology of hemolytic-uremic syndrome in Canadian children from 1986 to 1988. J Pediatr 1991; 119:218.

11.

Furlan M. , Robles R. , Galbusera M. , et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome. N Engl J Med 1998;26:1578.

12.

Furlan M. , Robles R. , Solenthaler M. , et al, Acquired deficiency of von Willebrand factor-cleaving protease in patients with thrombotic thrombocytopenic purpura. Blood 1998;91:2839.

13.

Antman KH , Skarin AT , Mayer RJ , et al. Microangiopathic hemolytic anemia and cancer. Cancer 1979;58:377.

14.

Sheldon R. Slaughter D. A syndrome of microangiopathic hemolytic anemia, renal impairment, and pulmonary edema in chemotherapy-treated patients with adenocarcinoma. Cancer 1986;58: 1428.

15.

Mori Y. , Wada H. , Tamaki S. , et al. Outcome, of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome in Japan. Clin Appl Thromb Hemost 1999;5:110.

16.

Abumiya T. , Enjyoji K. , Kokawa T. , et al. An antitissue factor pathway inhibitor (TFPI) monoclonal antibody recognized the third kunitz domain (K3) of free-form TFPI but not lipoprotein-associated forms in plasma. J Biochem 1995;118:178.

17.

Kokawa T. , Enjyoji K. , Kumeda K. , et al. Measurement of free form of tissue factor pathway inhibitor (TFPI) antigen in hypertipidmia: Relationship between free form and endotherial cell-associated forms of TFPI. Arterioscler Thromb Vasc Biol 1996;16:802.

18.

Kamei S. , Kamikubo Y. , Hamura T. , et al. Amino acid sequence and inhibitory activity of rhesus monkey tissue factor pathway inhibitor (TFPI): comparison with human TFPI. J Biochem 1994:115:708.

19.

Uchiyama H. , Hiraishi S. , Ohtani H. , et al. Plasma thrombomodulin is originated by damage of endotherial cell. Thromb Haemost 1989;62:276.

20.

Giddings JC , Coles P. , Williams BD , Comparison of thrombomodulin and von Willebrand factor antigen in human plasma in various disease. Thromb Haemost 1989;62:333.

21.

Bauer KA , Kass BL BeeleF DL , et al. Detection of protein C activa tion in humans. J Clin Invest 1984:74:2033.

22.

Buller Hrj , Ten Cafe JW Acquired antithrombin III defiecency: laboratory diagnosis, incidence, clinical implication, and treatment antithrombin III concentrate. Am J Med 1989:87:3B44S.

23.

Uchiba M. , Okajima K. , Hurakami K. , et al. Endotoxin induced pulmonary vascular injury is mainly mediated by activated leukocytes of rats. Thromb Res 1995;78:117.